Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Bottom Line Numbers To Date

"Assuming there are still over 400 potential licensees to sign, it would mean that there could be up to $1.154M in Net Profit to PTSC if they are able to sign all of them before 2015. Since there are more than likely MORE Small Companies to Big Companies to be signed than the currently signed ratio has contained, I'd say it would be wise to discount that number by 50%, "


Two things: 1) - I think the mix of companies yet to sign (small vs. big) may parallel fairly close to what we have done so far, so I think discounting the number by 50% is too aggressive. 2) - I think one would need to factor in that the first 37 licenses went off at significantly discounted values (i.e. 'early movers'), thus projecting out at the-already-established baseline is likely a understatement.

Thus, if the total take by PDS so far is $242mm and this is discounted by 30% for early movers, and we are only 10% of the way through the infringers, you would arrive at a total MMP value of well over $3 billion. For ease of computation, let's round down to the nearest billion: 3, and knock off an estimated 15% for expenses which takes you down to $2.5 billion. PTSC share = $1.25 billion, which after tax would be about $750mm, and that equates to a 'cash-only' book value of $2 share before considering anything else.

At .35 sp today, we should be an excellent candidate for a '6-bagger'; if not a '10-bagger' or more. The only issue is, how does the MMP value become exposed, communicated, realized, and built upon? We may have a couple people on board now who can help us; we still have a couple who cannot.

Best

Share
New Message
Please login to post a reply